Financial Performance - As of December 31, 2025, the company reported a net income of $396,872, primarily from interest earned on marketable securities held in the Trust Account totaling $3,089,290[272]. - The company incurred operating costs of $2,717,289 for the year ended December 31, 2025[272]. - The company has a working capital deficit of $2,079,709 as of December 31, 2025, with only $25,745 in its operating bank account[270]. IPO and Trust Account - The company completed its IPO on February 14, 2025, raising gross proceeds of $86,250,000 from the issuance of 8,625,000 Units at $10.00 per Unit[267]. - A total of $86,250,000 was deposited into a Trust Account, which will be used for redemptions upon completion of a business combination or liquidation if not completed within the required timeframe[269]. - The underwriters are entitled to a deferred fee of $3,450,000, payable only upon successful completion of a business combination[276]. Business Combination - The company entered into a Business Combination Agreement on October 13, 2025, to merge with GOWell Technology Limited, with PubCo continuing as the surviving entity[263]. - The company has until August 14, 2026, to consummate a business combination, after which mandatory liquidation will occur if not completed[271]. Administrative Changes - The company terminated its Administrative Services Agreement with the Prior Sponsor on September 9, 2025, resulting in the forgiveness of $12,502 in outstanding fees[273]. - The company has not yet commenced operations and will not generate operating revenues until the completion of an initial business combination[257].

Financial Performance - As of December 31, 2025, the company reported a net income of $396,872, primarily from interest earned on marketable securities held in the Trust Account totaling $3,089,290[272]. - The company incurred a net loss of $7,712 for the period from May 31, 2024, to December 31, 2024, primarily due to formation and audit-related expenses[272]. Initial Public Offering (IPO) - The company completed its IPO on February 14, 2025, raising gross proceeds of $86,250,000 from the issuance of 8,625,000 Units at $10.00 per Unit[267]. - A total of $86,250,000 was deposited into a Trust Account, which will be used for redemptions upon the completion of a business combination or liquidation if not completed within the required timeframe[269]. - The underwriters are entitled to a deferred fee of $3,450,000, payable only upon the successful completion of a business combination[276]. Business Combination - The company entered into a Business Combination Agreement on October 13, 2025, to merge with GOWell Technology Limited, with PubCo continuing as the surviving entity[263]. - The company has until August 14, 2026, to consummate a business combination, after which mandatory liquidation will occur if not completed[271]. Operational Status - The company has a working capital deficit of $2,079,709 as of December 31, 2025, with only $25,745 in its operating bank account[270]. - The company has not commenced operations as of December 31, 2025, and will not generate operating revenues until the completion of an initial business combination[257]. - The company terminated its Administrative Services Agreement with the Prior Sponsor on September 9, 2025, resulting in the forgiveness of $12,502 in outstanding fees[273].

Financial Performance - Net sales increased by 5.7% to R$50,116 million in 2025 from R$47,403 million in 2024, driven by higher pulp sales and the incorporation of Suzano Packaging's revenues[366] - Net sales from pulp increased by 0.6% to R$37,816 million in 2025, attributed to a 15.0% increase in sales volume despite a 15.6% decrease in pulp prices in U.S. dollars[367] - Gross profit decreased by 18.9% to R$16,226 million in 2025, mainly due to lower net average pulp prices[373] - Net income increased by 290.7% to R$13,438 million in 2025 from a loss of R$7,045 million in 2024[382] - Operating profit before net financial income decreased by 32.1% to R$10,649 million in 2025 from R$15,691 million in 2024, reflecting the factors mentioned above[379] Sales and Pricing - Average international pulp price decreased by 15.8% to US$542/ton in 2025 from US$644/ton in 2024[369] - The primary trends influencing sales and production include pulp purchase patterns by paper producers, pulp and paper prices, and global economic conditions[461] Costs and Expenses - Total cost of sales rose by 23.7% to R$33,890 million in 2025, primarily due to higher volume and currency appreciation[372] - Selling expenses increased by 12.7% to R$3,313 million in 2025, driven by higher sales volume[374] - General and administrative expenses rose by 6.5% to R$2,790 million in 2025, influenced by the incorporation of Suzano Packaging US[374] Cash Flow and Indebtedness - Cash and cash equivalents as of December 31, 2025, were R$15,180 million, up from R$9,019 million in 2024[385] - The company reported net cash provided by operating activities of R$18,152.2 million in 2025, a decrease of R$2,452.2 million compared to R$20,604.4 million in 2024, primarily due to lower pulp prices and currency fluctuations[392] - Total consolidated outstanding indebtedness as of December 31, 2025, was R$94,801.3 million, with R$3,004.9 million classified as current indebtedness[398] Capital Expenditures and Investments - Capital expenditures for 2025 amounted to R$13,298.7 million, down from R$17,119.8 million in 2024, with R$7,880.0 million allocated to industrial and forestry maintenance[395] - The company plans to invest R$7,254.5 million in maintenance capex for 2026, primarily financed by cash and cash equivalents[389] - The approved budget for capital expenditures in 2026 is R$10,947.4 million, reflecting a decrease due to project schedules and lower investment intensity[397] Research and Development - In 2025, the company invested R$199.2 million in research and development to enhance forestry productivity and develop innovative products[425] - The number of eucalyptus clones recommended for operational planting increased from 51 to 70, improving genetic diversity and productivity indicators[427] - The company produced over 5 million seedlings in 2025, significantly expanding its capacity for high-performance genetic materials[428] - Eucafluff production capacity increased by more than fourfold, adding 340,000 tons to the market in 2025[444] - The launch of Verto Plus duplex paperboard and LIN Design coated white paper aimed to enhance packaging standards and functionality[445] - The company achieved an average fiber substitution success rate of 12 percentage points in paper formulations across joint projects with over 70 clients[441] - In 2025, FuturaGene submitted an inquiry letter for a gene-edited eucalyptus, potentially streamlining industrial processing and reducing input requirements[437] - The company holds a total of 780 patents, 82 industrial designs, and 78 protected eucalyptus varieties, reflecting its commitment to innovation[457] - Significant advances in digital technologies were made, particularly in artificial intelligence for R&D knowledge management and research ERP system development[454] Trademark and Market Expansion - In 2025, the company requested 130 and received 42 registrations for 11 new trademarks, including notable names like Suzano Packaging and Eucaprime[460] - The company is actively expanding its trademark portfolio across five continents, including the United States, Canada, and various countries in Europe, Latin America, Africa, Asia, and Oceania[459] Financing Activities - The company issued Rural Product Notes totaling R$2,500.0 million and debentures amounting to R$179.0 million, expected to be settled by early April 2026[387] - Financing activities resulted in a net cash outflow of R$1,819.6 million in 2025, with major sources including R$23,871.8 million in loans and financing[394] - The company anticipates accessing capital or banking markets for long-term capital needs, using a ten-year model to monitor various scenarios[391] - As of December 31, 2025, the company had access to a Revolving Credit Facility (RCF) totaling US$1,775.0 million, extended until February 2031[386]

Drug Development and Clinical Trials - PLX-200 is the most advanced drug candidate, targeting several lysosomal storage diseases (LSDs) and expected to enter a Phase 2 proof-of-concept trial named SOTERIA in the second half of 2026[20]. - The FDA has granted authorization for PLX-200 to initiate pivotal trials in CLN2 and CLN3, although these trials are currently delayed[21]. - PLX-200 is prioritized for clinical development through the SOTERIA trial, expected to initiate in the second half of 2026, targeting approximately 25% of the LSD patient population[41]. - The company plans to optimize pivotal trials for PLX-200 in CLN2 and CLN3, which represent the largest patient populations among 13 known NCL subtypes, with trials delayed due to the COVID-19 pandemic[41]. - The clinical development strategy for PLX-200 prioritizes the launch of Phase 2 SOTERIA, with FDA authorization to initiate in October 2025, focusing on multiple indications beyond CLN2 and CLN3[96]. - Enrollment for the CLN2 and CLN3 cohorts is expected to begin in the second half of 2026, with the first interim analysis anticipated one year after the last patient enrollment[99]. - The primary objective of the SOTERIA trial is to evaluate the safety and tolerability of PLX-200 in 18 trial participants aged 2 to 15 years[103]. - PLX-200-003 is a Phase 3 clinical trial for CLN3, with primary objectives to evaluate safety and efficacy compared to a placebo group after 60 weeks of maintenance therapy[104]. - A potential optimization of the PLX-200-003 trial design may shift to a single-arm, open-label trial based on community feedback[105]. Patient Population and Market Potential - The company estimates approximately 50,000 LSD patients in the U.S., Europe, and select regions of the rest of the world, assuming an incidence rate of one in 5,000 births[22]. - Approximately 50,000 LSD patients are estimated to exist in the US, Europe, and select regions, with a focus on developing therapies for NCLs and other LSDs lacking patient-friendly, disease-modifying treatments[44]. - NCLs represent about 15% of the LSD population, equating to roughly 7,700 patients, with only CLN2 having an established standard of care[48]. - Krabbe disease affects approximately 6,700 patients globally, with an incidence rate of 0.3 to 2.6 per 100,000 live births, categorized into four subtypes based on age of symptom onset[55]. - Tay-Sachs disease has a prevalence of approximately one in 100,000 births, while Sandhoff disease is rarer at about 0.67 per 100,000 births, with around 1,200 Sandhoff patients estimated in the US, Europe, and select regions[52]. Drug Designations and Regulatory Pathways - PLX-200 has received three orphan drug designations for treating all 13 subtypes of NCLs, GM2 gangliosidoses, and Krabbe disease, along with fast track designations for CLN2 and CLN3[21]. - The FDA indicated that the 505(b)(2) regulatory pathway is appropriate for PLX-200, allowing the use of existing data to accelerate clinical development and reduce costs[41]. - The FDA has granted three Orphan Drug Designations (ODD) to PLX-200 for treating all 13 sub-types of NCLs, Tay-Sachs, Sandhoff diseases, and Krabbe disease, along with Fast Track designation for CLN3[66]. - PLX-300 has received three orphan drug designations (ODDs) for treating GM2 gangliosidosis, Krabbe disease, and NPD types A and B[113]. - PLX-300 has also obtained orphan drug designation from the FDA for GM2 gangliosidosis, Krabbe disease, and NPD type A and B, entitling it to similar marketing exclusivity benefits[177]. Therapeutic Mechanisms and Efficacy - PLX-200 is designed to be administered through a novel oral solution, enhancing its potential to become the standard of care across multiple LSDs[20]. - The small molecule pipeline demonstrates multiple modes of action, including lysosomal biogenesis and reduction in neural inflammation, which are critical for treating LSDs[30]. - PLX-200 has demonstrated potential in preclinical studies to improve locomotor activity and motor coordination in CLN3 mouse models, suggesting benefits in preserving neuronal function[75]. - In preclinical studies, PLX-200 has been shown to reduce the accumulation of storage materials in CLN2 mice, quantified by SCMAS positive immunofluorescence[78]. - PLX-200 has exhibited significant improvement in hypolocomotion and increased longevity in GALC-deficient mice by 11-13 days, indicating its therapeutic potential in Krabbe disease[84]. - The drug candidate activates PPARα, promoting the expression of TFEB genes, which are crucial for lysosomal biogenesis and cellular clearance in neurodegenerative diseases[67]. - PLX-100, a novel oral therapy, aims to improve enzymatic activities in multiple LSD indications and has received one ODD for CLN2[131]. - Preclinical studies indicated that PLX-100 upregulated TPP1 mRNA and protein levels significantly, suggesting therapeutic potential for CLN2[137]. - PLX-100 demonstrated enhanced expression of TFEB by more than three-fold compared to PLX-200 alone, indicating increased potency in treating LSDs[139]. - PLX-100 has been shown to significantly increase myelin markers MBP and PLP in the cerebellum and corpus callosum of GALC mice, indicating therapeutic potential for Krabbe disease[141]. - PLX-100 reduced glial activation markers GFAP and iNOS in both the cerebellum and corpus callosum, suggesting a decrease in neuroinflammation[144]. - Preclinical studies for PLX-300 demonstrated reduced glyconjugate accumulation and improved neurobehavioral scores in animal models of Sandhoff disease[116]. - Preclinical studies indicate that PLX-400, a novel intranasally deliverable gene therapy, has prolonged the lifespan of CLN2 mice when used as a monotherapy or in combination with PLX-200[153]. Financial and Investment Overview - The company has raised $21.7 million since its inception in 2014, supported by institutional and private investors[35]. - The company plans to build a commercial infrastructure to support the sale of approved products, potentially including a dedicated sales force or partnerships with pharmaceutical companies[158]. - The company has no immediate plans to establish its own manufacturing facilities and relies on third-party CMOs for production, which may lead to delays if current suppliers become unavailable[157]. Intellectual Property and Patent Strategy - The patent portfolio consists of six distinct patent application families, including five issued patents in the U.S. and six in foreign jurisdictions, with a focus on lysosomal storage disorders[169]. - The company holds exclusive rights to four patent families related to the use of fibrates for treating lysosomal storage disorders, with key patents expiring between 2034 and 2044[170]. - The last licensed patent under the 2016 Rush License Agreement is estimated to expire in 2044, while the 2022 Rush License Agreement is expected to last until 2040[162][168]. - The company is pursuing patent protection for PLX-400, with a pending patent in the U.S. and an estimated expiration date in 2040, which highlights ongoing innovation efforts[178]. - The company plans to apply for patent term extensions for its product candidates, which could provide additional market exclusivity beyond standard patent terms[179]. Competitive Landscape and Market Challenges - The company faces competition from established pharmaceutical companies and emerging biotech firms, which may have advantages in resources and market experience[181]. - There is currently one established standard of care for CLN2 disease, with cerliponase alfa approved in 2017, indicating a competitive landscape for treatments of neuronal ceroid lipofuscinoses[182]. - For Tay-Sachs and Sandhoff diseases, there is limited direct competition as no established standard of care exists, but other companies are developing competitive candidates[183]. - The FDA's regulatory process requires substantial time and financial resources, with significant data needed to demonstrate safety and efficacy before marketing approval can be obtained[188]. - Non-compliance with FDA regulations during the development or approval process can lead to severe sanctions, impacting the company's product candidates[189]. FDA Review and Approval Process - The FDA aims to review standard NDAs within ten months and priority NDAs within six months after filing[205]. - The FDA may issue a Complete Response letter detailing deficiencies in a BLA, which may require additional testing or information for approval[202]. - The FDA conducts preliminary reviews of NDAs within 60 days to determine completeness before acceptance for filing[210]. - The FDA may require a REMS plan to ensure the benefits of a drug outweigh its risks, which can include various risk management tools[208]. - Products may receive accelerated approval if they show effects on surrogate endpoints likely to predict clinical benefit, with post-marketing studies required[217]. - The Pediatric Research Equity Act mandates pediatric data in BLAs for relevant subpopulations, with potential deferrals or waivers available[200]. - The FDA may limit approved indications for a product and require post-approval studies to monitor safety and effectiveness[214]. - The FDA typically inspects manufacturing facilities and clinical trial sites before approving an NDA to ensure compliance with safety standards[212]. RMAT Designation and Fast Track Program - The FDA established the RMAT designation in 2017 to expedite the development and review of certain drugs, including cell therapies and tissue engineering products[218]. - RMAT designation allows for accelerated approval based on surrogate or intermediate endpoints that predict long-term clinical benefits[219]. - Products with RMAT designation can benefit from more frequent meetings with the FDA and eligibility for rolling and priority reviews[218]. - A product can receive breakthrough therapy designation if preliminary clinical evidence shows substantial improvement over existing therapies[219]. - The RMAT program includes features of the Fast Track program, with intensified FDA interaction starting as early as Phase 1[219]. - Post-approval requirements for RMAT products may include clinical evidence submissions and real-world evidence collection[219]. - The RMAT designation aims to address serious or life-threatening diseases with unmet medical needs[218]. - Companies can expand clinical trials to additional sites to fulfill RMAT requirements[219]. - The FDA may allow post-approval monitoring of all patients treated with the therapy prior to approval[219].

Trust Structure and Operations - The Trust holds a net profits interest entitling it to receive 80% of the net profits from oil and natural gas production from the Underlying Properties[45]. - The Trust's business activities are limited to owning the net profits interest and related activities, with no management control over the Underlying Properties[52]. - The Trust has no employees, and administrative functions are performed by the Trustee under the Trust Agreement[53]. - The Trust is passive and lacks the ability to influence operations or development of the Underlying Properties, relying solely on cash distributions from the Net Profits Interest[203]. - Trust unitholders have limited ability to enforce provisions of the Conveyance, and the Sponsor's liability is limited under the Trust Agreement[210]. Financial Performance and Distributions - The Trust's annual cash proceeds attributable to the net profits interest were less than $2 million for each of any two consecutive years, which could trigger dissolution[64]. - The Trust's cash distributions to unitholders are made after paying obligations and expenses, with any remaining proceeds from the net profits interest distributed monthly[57]. - The Trust's cash available for distribution is affected by the operation of gathering, transportation, and processing facilities, with potential curtailments in production due to various factors[180]. - The Trust's financial condition may be adversely affected by fluctuating oil and natural gas prices, which could reduce cash distributions to unitholders[149]. - A substantial decline in oil or natural gas prices could reduce profits and cash available for distribution to Trust unitholders[162]. - The Trust's distributions may be considered a return of capital due to the depleting nature of the assets, potentially leading to a cessation of distributions if production ceases[188]. - The Trust's financial statements are prepared on a modified cash basis, differing from GAAP, which may affect the perception of financial health[212]. Regulatory and Environmental Compliance - The Sponsor believes it is in substantial compliance with all existing environmental laws and regulations, which may affect profitability due to increased regulatory burdens[109]. - The operations of the Underlying Properties are subject to stringent environmental regulations, which could increase costs and liabilities[218]. - The Clean Water Act imposes strict controls on pollutant discharges, with wastewater discharges from onshore oil and gas activities prohibited east of the 98 meridian[115]. - The EPA's 2024 rule will regulate volatile organic compound and methane emissions from oil and gas sources constructed or modified after December 2022, with compliance deadlines for existing sources expected by 2029[127]. - The regulatory landscape regarding "waters of the United States" remains unsettled due to ongoing litigation, impacting the Sponsor's permitting obligations[118]. - Changes in regulations regarding GHG emissions could make the Sponsor's products more or less desirable compared to competing energy sources[136]. - Compliance with federal and state laws governing conservation matters may limit production levels and affect Trust distributions[225]. Market and Operational Risks - The ability of OPEC and other oil-exporting nations to maintain production levels significantly impacts commodity prices, affecting the Trust's revenue[149]. - The oil and natural gas reserves are depleting assets, leading to diminished production over time, which could affect future cash distributions[149]. - Shortages of equipment and qualified personnel could increase operational costs and reduce cash available for distribution to Trust unitholders[179]. - The Trust is subject to competitive conditions in the oil and natural gas industry, impacting its net profits interest indirectly[63]. - The Trust's operations are concentrated in Texas, Louisiana, and New Mexico, exposing it to operational and regulatory risks in these areas[181]. Taxation and Financial Reporting - The Trust is classified as a grantor trust for U.S. federal income tax purposes, meaning it is not subject to tax at the trust level, and unitholders are taxed on their proportionate share of income[99]. - The highest marginal U.S. federal income tax rate applicable to ordinary income is 37%, while the rate for long-term capital gains is generally 20%[101]. - The Trust files annual information returns reporting all items of income, gain, loss, deduction, and credit to unitholders based on record ownership[100]. - The Trust has not sought IRS ruling on tax treatment, which could lead to complex tax reporting and reduced cash distributions if deemed not a "grantor trust"[243]. Cybersecurity Risks - Cybersecurity risks have increased due to reliance on IT systems, potentially leading to data theft and operational disruptions[239]. - Cyber-attacks on third-party oil and gas distribution systems could delay market deliveries, adversely affecting business operations[240]. - The Trustee's operations are heavily dependent on IT systems, with risks of data loss and cyber-attacks from both external and internal sources[241]. - A cyber-attack could compromise confidential information and lead to litigation, increased costs, and regulatory penalties[242].

Financial Position - As of December 31, 2025, the company had a net loss of $60,111, entirely from general and administrative expenses[285]. - The company had $0 cash and a working capital deficit of $286,658 as of December 31, 2025[287]. - The company had $0 borrowings under Working Capital Loans as of December 31, 2025[294]. - As of December 31, 2025, the company had no long-term debt, capital lease obligations, or long-term liabilities[312]. - As of December 31, 2025, the Company had no long-term debt, capital lease obligations, operating lease obligations, or long-term liabilities[312]. Initial Public Offering (IPO) - The Initial Public Offering (IPO) generated gross proceeds of $300,000,000 from the sale of 30,000,000 Units at $10.00 per Unit[288]. - An additional $45,000,000 was raised through the sale of 4,500,000 Units under the Over-Allotment Option, also priced at $10.00 per Unit[290]. - A total of $345,000,000 from the IPO and Over-Allotment Option was placed in the Trust Account, invested in money market funds or U.S. government treasury obligations[291]. - The company granted underwriters an Over-Allotment Option to purchase up to 4,500,000 additional Units[288]. - The company granted underwriters a 45-day option to purchase up to 4,500,000 Over-Allotment Option Units, which was exercised on January 23, 2026[314]. Business Operations - The company has no current operations or revenues and will not generate operating revenues until after completing its initial business combination[284]. - The company has not conducted any operations to date, and thus no unaudited quarterly operating data is included in the report[312]. Trust Account and Financing - The company intends to use substantially all funds in the Trust Account to complete its initial business combination and may withdraw interest for permitted withdrawals[292]. - The company may need additional financing to complete its initial business combination if the cash required exceeds the available proceeds from the Trust Account[300]. - The proceeds in the Trust Account are invested in money market funds or U.S. government treasury obligations, with no material exposure to interest rate risk expected[305]. Expenses and Agreements - The company expects to incur approximately $1,309,000 for legal, accounting, due diligence, and other expenses related to business combinations[298]. - The company pays $15,000 per month for administrative services, which will cease upon completion of a business combination[310]. - The company entered into an Administrative Services and Indemnification Agreement, agreeing to pay $15,000 per month for office space and administrative services[313]. - The underwriters are entitled to a deferred fee of $0.35 per Unit, totaling $12,075,000, payable only if a business combination is completed[315]. - The company has agreed to indemnify the Sponsor from claims related to its operations, with the indemnified parties unable to access Trust Account funds[310]. Accounting Policies - The company has identified critical accounting policies but reported no critical accounting estimates as of December 31, 2025[317]. - The company accounts for Class A ordinary shares subject to possible redemption as temporary equity, adjusting their carrying value to equal redemption value at each reporting period[318]. - Class A ordinary shares subject to possible redemption are classified as temporary equity and measured at fair value, with changes recognized immediately[318]. - The Company recognizes changes in redemption value of Class A ordinary shares immediately and adjusts the carrying value accordingly[319]. - Management does not anticipate that recently issued accounting standards will materially affect the Company's financial statements[320].

Economic Vulnerabilities - The company operates primarily in North Carolina and focuses on the Southeastern United States, making it vulnerable to economic downturns in these regions [100]. - Revenue and profit are generated from infrastructure projects, which are subject to cyclical fluctuations due to economic conditions, supply chain disruptions, and inflationary pressures [98]. - The company faces risks from potential utility shortages and price increases in its operating markets, which could lead to additional costs and project delays [103]. - Changes in population growth rates in key markets could affect housing demand, impacting the company's growth plans and financial condition [122]. - Federal highway funding is subject to uncertainties, and any reduction in funding could materially adversely affect the company's results of operations [134]. - The company faces intense competition in the public infrastructure construction industry, which could reduce the number of new contracts awarded [128]. Operational Risks - The company relies heavily on third-party suppliers for materials, and price increases for materials such as fuel, concrete, and steel have adversely impacted operating margins [102]. - Fixed-unit price and lump sum contracts account for the majority of revenues, requiring accurate cost estimation to avoid losses from cost overruns [104]. - The timing of contract awards is unpredictable, leading to potential mismatches in equipment and workforce allocation, which could incur additional costs [118]. - Natural disasters and severe weather conditions pose risks that could increase costs, cause project delays, and reduce consumer demand [119]. - Labor shortages and increased turnover rates could lead to higher labor costs and negatively impact project completion [143]. - The company may not be able to recover on claims or change orders against clients, negatively impacting cash flows [138]. Financial Performance and Risks - Interest rate fluctuations may adversely affect the company's financial performance, as borrowings may bear interest at variable rates [114]. - The company has historically experienced variability in quarterly results due to seasonal factors, generating less revenue during winter months [124]. - Material weaknesses in internal controls over financial reporting have been identified, which could affect the accuracy of financial results if not remediated [184]. - The company’s ability to generate cash flow is influenced by various factors, including operational performance and market conditions, which could impact liquidity [179]. - Future effective tax rates may be volatile and could adversely affect the company's financial condition due to various factors, including changes in tax laws [188]. - The company anticipates that future indebtedness will be recourse, which could increase financial risk and affect operational decisions [191]. Legal and Regulatory Risks - The company is subject to various employment-related laws and regulations, which could increase operational costs and expose it to fines [144]. - The company is currently subject to employee-related legal proceedings, which may incur damages and expenses that could adversely affect its financial condition [145]. - The company may face challenges in obtaining insurance coverage for certain risks, which could lead to significant uninsured losses [121]. - Environmental regulations may require significant expenditures, potentially adversely affecting the company's financial position and results of operations [152]. - The company is subject to evolving data privacy and cybersecurity regulations, which may increase compliance costs and expose it to significant fines if not adhered to [165]. Growth and Acquisition Strategies - The company intends to pursue growth through acquisitions but faces risks related to the successful integration and performance of acquired businesses [166]. - The company has not entered into any new acquisition agreements as of the report date, indicating a cautious approach to expansion [166]. - The company may need to raise additional capital for working capital and acquisitions, which could be difficult under unfavorable market conditions [177]. - The company faces risks related to acquisitions, including integration challenges and potential financial discrepancies in acquired businesses [170]. Shareholder and Market Considerations - The company may face restrictions on declaring dividends due to insufficient funds from Cardinal's distributions [197]. - The Continuing Equity Holders control approximately 61.0% of the voting power of all outstanding shares as of December 31, 2025, significantly influencing corporate decisions [207]. - The stock price may experience significant volatility, potentially affecting the ability to resell shares at or above the purchase price [209]. - Factors affecting stock price include operational results differing from analyst expectations, changes in technology, and economic conditions [210]. - The company may issue additional securities in connection with investments or acquisitions, which could constitute a material portion of the outstanding shares and result in further dilution [233]. Financial Obligations and Agreements - The Tax Receivable Agreement requires the company to make cash payments equal to 85% of tax benefits realized, which are expected to be substantial [198]. - Payments under the Tax Receivable Agreement will reduce overall cash flow available for reinvestment in the business [200]. - If the company cannot make timely payments under the Tax Receivable Agreement, unpaid amounts will accrue interest and may lead to a material breach [200]. - The company may need to incur debt to finance obligations under the Tax Receivable Agreement if cash resources are insufficient [205]. - Payments made under the Tax Receivable Agreement are not reimbursable if tax benefits are disallowed by tax authorities [206]. Debt and Interest Rate Management - As of December 31, 2025, the company had $120.0 million in borrowings under the October 2025 Credit Facility, with an interest rate of 6.83% [191]. - The company held cash of $97.1 million as of December 31, 2025 [392]. - In January 2026, the company entered into an interest rate swap for $60.0 million notional of the $120.0 million total facility [392]. - The interest rate swap fixes the overall rate assuming a term SOFR rate at 3.8% [392]. - A 100-basis point increase or decrease in interest rates would result in a change of approximately $1.2 million in annual interest expense [392].

Financial Performance - Q4 2025 GAAP net loss attributable to common stockholders was $(0.17) per share, while FY 2025 net loss was $(0.14) per share[10]. - Distributable Earnings for Q4 2025 were $(0.00) per share, and for FY 2025, they were $0.14 per share[10]. - The company reported a net loss of $2.745 million for the year, resulting in a basic and diluted loss per share of $0.14[48]. - Distributable earnings for the year were reported at $4.021 million, with a distributable earnings per share of $0.08[53]. - The Company declared dividends of $0.22 per weighted average share of common stock[48]. Assets and Liabilities - Total assets as of December 31, 2025, were $1.216 billion, with total liabilities of $996.893 million[11]. - Total liabilities as of December 31, 2025, were $996.893 million, compared to $890 million in the previous year[46]. - Total stockholders' equity was $218.987 million, leading to a book value per share of common stock of $3.03[57]. - The Company held cash and cash equivalents of $23.1 million and had a leverage ratio of 4.6x[11]. Loan Portfolio - The investment portfolio consisted of $1.1 billion in floating-rate CRE loans, with 92.6% collateralized by multifamily assets[20]. - The Company's portfolio had a weighted average risk rating of 3.2, with 91.2% of loans performing[32]. - The company has a diversified multifamily loan portfolio across various states, with loans ranging from $5.99 million to $43.66 million[42][44]. - The maturity dates of loans in the portfolio extend from 2025 to 2028, indicating a long-term investment strategy[42][44]. - The average interest rate on the multifamily loans is approximately 3.33%, which may provide stable income in a fluctuating interest rate environment[44]. - The company has a significant focus on multifamily properties, which constitute the majority of its loan portfolio[42][44]. Debt and Financing - Total debt amounts to $1,215.6 million, representing 78.1% of total capitalization[34]. - Secured financing agreements carry a value of $909.9 million, which includes $2 million of unamortized debt issuance costs[35]. - The secured financing agreements have a weighted average interest rate of 4.9%, indicating the cost of borrowing for the company[34]. - Subsequent to Q4 2025, the Company extended the maturity of its corporate debt to 2030 and revised the interest rate to a fixed 9.75%[10]. - The company’s term loans are shown at par value, reflecting a conservative approach to debt management[35]. Income and Revenue - Net interest income for the year ended December 31, 2025, was $25.113 million, with total revenues of $76.653 million from commercial mortgage loans held-for-investment[48]. Credit Losses - The allowance for credit losses at the end of the period was $22.658 million, up from $11.320 million at the beginning of the year[51]. - The company experienced a provision for credit losses of $14.449 million during the year[51].

Financial Performance - Net income attributable to Assured Guaranty Ltd. for Q4 2025 was $119 million, compared to $18 million in Q4 2024, representing a significant increase of 561%[6] - Adjusted operating income for the year ended December 31, 2025, was $445 million, up from $389 million in 2024, reflecting a growth of 14.4%[6] - Total revenues for the year ended December 31, 2025, reached $1,110 million, a significant increase of 27.3% compared to $872 million in 2024[14] - Net income attributable to AGL for the year ended December 31, 2025, was $503 million, up 33.8% from $376 million in 2024[14] - Basic earnings per share increased to $10.39 for the year ended December 31, 2025, compared to $7.01 in 2024, reflecting a growth of 48.8%[14] - Total expenses for the year ended December 31, 2025, amounted to $550 million, with employee compensation and benefits expenses at $209 million and interest expense at $89 million[32] - The company experienced a net realized investment loss of $40 million for the year ended December 31, 2025, while reporting a net realized investment gain of $9 million for the year ended December 31, 2024[32][35] Revenue and Premiums - Gross written premiums (GWP) for Q4 2025 were $61 million, a decrease from $186 million in Q4 2024, indicating a decline of 67.4%[6] - The present value of new business production (PVP) for Q4 2025 was $92 million, down from $121 million in Q4 2024, a decrease of 24.0%[6] - The total present value of premiums (PVP) for the year ended December 31, 2025, was $286 million, compared to $402 million in 2024[67] - Net earned premiums for the three months ended December 31, 2025, were $(1) million, consistent with the same period in 2024[142] - Net earned premiums for 2025 were $380 million, a decrease of 5.7% from $403 million in 2024[147] Shareholder Returns - Total capital returned to common shareholders in 2025 was $569 million, slightly down from $570 million in 2024[6] - The company repurchased $500 million in common shares during 2025, compared to $502 million in 2024, indicating a stable capital return strategy[6] - Shareholders' equity attributable to AGL increased to $5,663 million as of December 31, 2025, up from $5,495 million in 2024, representing a growth of 3.1%[11] - Adjusted operating shareholders' equity per share increased to $126.78 in 2025 from $114.75 in 2024, reflecting a growth of approximately 9%[156] Assets and Liabilities - Total assets increased to $12,176 million as of December 31, 2025, compared to $11,901 million in 2024, indicating a growth of 2.3%[16] - Total liabilities were $6,387 million as of December 31, 2025, compared to $6,348 million in 2024, reflecting a marginal increase of 0.6%[16] - Financial guaranty net debt service outstanding rose to $440.8 billion as of December 31, 2025, compared to $416.0 billion in 2024, marking a 6.7% increase[11] Investment Performance - The company reported fair value gains on credit derivatives of $121 million for the year ended December 31, 2025, compared to $24 million in 2024, showing a substantial increase[14] - The company reported a fair value gain on credit derivatives of $3 million for the three months ended December 31, 2025[26] - The total net investment income for the year ended December 31, 2025, was $359 million, slightly down from $340 million in 2024, a decrease of 5.6%[55] - Fair value gains on trading securities for the Insurance segment were $2 million in Q4 2025, compared to no gains in Q4 2024[59] Segment Performance - The insurance segment reported an adjusted operating income of $508 million for the year, compared to $525 million in 2024, a decrease of 3.2%[6] - The asset management segment generated an adjusted operating income of $20 million in 2025, up from $5 million in 2024, reflecting a significant increase of 300%[6] - Segment revenues for the Insurance segment in Q4 2025 reached $226 million, up from $199 million in Q4 2024, representing a growth of 13.6%[59] - The total funds managed by Sound Point and AHP generated $24 million in earnings in Q4 2025, compared to $15 million in Q4 2024, an increase of 60%[51] Tax and Regulatory - The effective tax rate on net income for 2025 was 17.9%, compared to 19.7% in 2024, showing a reduction of 1.8 percentage points[6] - The provision for income taxes for the year ended December 31, 2025, was $119 million, while it was $96 million for the year ended December 31, 2024[32][35] Future Projections - The company expects a total of $1,314 million in future credit derivative revenues from 2026 to 2030[77] - The company anticipates a total of $3,615 million in future financial guaranty net premium revenue by the end of 2025[77] - Estimated net debt service amortization for 2025 is projected at $440.8 billion, with a gradual decrease expected in subsequent years[77] Market Strategy - The company continues to focus on expanding its market presence in the U.K. and Spain, particularly in renewable energy and infrastructure finance sectors[174]

Investment Portfolio - As of December 31, 2025, the company's mortgage loan investment portfolio consisted of 61 senior secured floating rate loans with an aggregate unpaid principal balance of $1.1 billion, having a weighted average coupon of 7.2% and a weighted average term to maturity of 1.7 years[26]. - During 2025, the company originated or acquired $403.9 million in loans, realized $266.6 million of loan repayments, and transitioned $62.6 million in loans to real estate owned, resulting in a net loan principal balance increase of $74.7 million[27]. - The company owned three multifamily properties with an aggregate carrying value of $49.1 million as of December 31, 2025[31]. - The company retained servicing rights associated with residential mortgage loans (MSRs) with an aggregate unpaid principal balance of approximately $54.6 million, with a carrying value of approximately $0.6 million[32]. - The company’s investment strategy focuses on transitional floating rate CRE mortgage loans, particularly in middle-market multifamily assets, and may adapt to changing market conditions[20]. - The company’s investments typically include first mortgage loans, mezzanine loans, preferred equity, and other CRE-related debt instruments, with a focus on loans greater than $5 million and up to 85% loan-to-value ratio[22][23]. Financing and Leverage - The company financed its investments through matched term non-recourse secured borrowings, including CRE collateralized loan obligations (CLO), which are not subject to margin calls or additional collateralization requirements[19]. - As of December 31, 2025, the company had total portfolio financing of $996.6 million, with various financing arrangements including a $663.8 million managed CLO providing $585.0 million of non-mark-to-market financing[36][37]. - The company aims to use leverage to increase potential returns, with a strategy to maintain appropriate leverage ratios based on the risk level of the investment portfolio[34]. - The leverage of the company's portfolio investments currently ranges between three and six times the amount of stockholders' equity, which creates significant risks[144]. - The company may incur substantial losses if borrowing costs increase, which could reduce cash flow available for distributions to stockholders[145]. Regulatory and Taxation - The company has elected to be taxed as a REIT since December 31, 2012, and must distribute at least 90% of its REIT taxable income to maintain this status[47][53]. - To maintain REIT qualification, at least 75% of gross income must come from real property-related investments[51]. - The company must ensure that no more than 50% of its outstanding shares are owned by five or fewer individuals to maintain REIT status[54]. - For fiscal year 2025, the company's taxable REIT subsidiary did not generate taxable income[49]. - The company is subject to various governmental regulations that could impact its operations and financial condition[45][46]. Risks and Challenges - The company faces risks related to interest rate fluctuations, which could adversely affect its ability to generate income and make distributions[62]. - The company faces competition from various institutional investors, which may impact its ability to generate targeted returns due to overlapping investment objectives and differing risk tolerances[39]. - The company is subject to prepayment risk, which may reduce interest income if reinvested in lower-yielding assets[72]. - Rising interest rates generally reduce the demand for mortgage loans, potentially affecting the volume of transitional floating-rate multifamily and CRE loans available to the company[81]. - The company may face potential losses if borrowers default on loans due to declines in net operating income or property values[97]. - The company may be impacted by natural disasters or significant climate changes, which could decrease property values and increase defaults[90]. - The company may experience delays in foreclosure processes due to deficiencies in third-party practices, increasing costs and potential loan loss severities[131]. - The company may be exposed to environmental liabilities related to properties it takes title to, which could significantly affect its financial condition[129]. Management and Conflicts of Interest - The company has no employees and is externally managed by a subsidiary of ORIX USA, which provides executive officers[44]. - The company relies heavily on its Manager for investment decisions, which may not always align with stockholder interests, potentially affecting returns[170]. - The Manager is subject to conflicts of interest due to its relationship with ORIX and its affiliates, which may not align with the best interests of the Company’s stockholders[172]. - The incentive fee for the Manager is based on core earnings, which may lead to a focus on riskier investments to maximize compensation[179]. - The Management Agreement with the Manager automatically renews annually, but termination without a suitable replacement could hinder the execution of the business plan[171]. Market Conditions - Interest rates have increased eleven times between 2022 and late 2024 due to rising inflation, impacting borrowing costs and potentially decreasing cash flows and market value of investments[157]. - The U.S. Federal Reserve began decreasing interest rates in 2024, but inflation remains above target levels, indicating ongoing challenges for real estate valuations[157]. - The company operates in a highly competitive market, which may limit its ability to acquire desirable investments and could affect pricing[117]. - A prolonged economic recession and declining real estate values could impair the company's assets and operations, increasing the likelihood of losses[118]. - Global trade disruptions and protectionist policies could lead to economic recessions and declines in real estate values, adversely affecting the company's loans and operations[119]. Governance and Ownership - The board of directors has the authority to issue additional shares of common or preferred stock, which may prevent changes in control that could benefit shareholders[206]. - Ownership limitations restrict any individual from owning more than 9.8% of the company's outstanding shares, which was recently reduced to 8.75% for non-exempt holders[207]. - The company has granted exemptions to the stock ownership limits for specific entities, including XL Bermuda Ltd and Lument Investment Holdings, LLC[208]. - Certain provisions of Maryland law may delay or prevent a change of control that could involve a premium price for shareholders[209]. - Control share provisions limit voting rights for shares acquired in a control share acquisition unless approved by a two-thirds majority of stockholders[211].